• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

年龄相关性黄斑变性

Age-related macular degeneration.

作者信息

Querques Giuseppe, Avellis Fernando Onofrio, Querques Lea, Bandello Francesco, Souied Eric H

机构信息

Service d'Ophtalmologie, Centre Hospitalier Intercommunal Créteil, Université Paris-Est Créteil, Créteil, France;

出版信息

Clin Ophthalmol. 2011;5:593-601. doi: 10.2147/OPTH.S10161. Epub 2011 May 18.

DOI:10.2147/OPTH.S10161
PMID:21654887
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3102591/
Abstract

CLINICAL QUESTION

Is there any new knowledge about the pathogenesis and treatment of age-related macular degeneration (AMD)?

RESULTS

We now understand better the biochemical and pathological pathways involved in the genesis of AMD. Treatment of exudative AMD is based on intravitreal injection of new antivascular endothelial growth factor drugs for which there does not yet exist a unique recognized strategy of administration. No therapies are actually available for atrophic AMD, despite some experimental new pharmacological approaches.

IMPLEMENTATION

strategy of administration, safety of intravitreal injection.

摘要

临床问题

关于年龄相关性黄斑变性（AMD）的发病机制和治疗有哪些新知识？

结果

我们现在对AMD发生过程中涉及的生化和病理途径有了更好的理解。渗出性AMD的治疗基于玻璃体内注射新型抗血管内皮生长因子药物，目前尚无统一认可的给药策略。尽管有一些新的实验性药理学方法，但目前尚无针对萎缩性AMD的有效疗法。

实施

给药策略、玻璃体内注射的安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90dc/3102591/35d8a438bc32/opth-5-593f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90dc/3102591/35d8a438bc32/opth-5-593f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90dc/3102591/35d8a438bc32/opth-5-593f1.jpg

相似文献

1
Age-related macular degeneration.年龄相关性黄斑变性
Clin Ophthalmol. 2011;5:593-601. doi: 10.2147/OPTH.S10161. Epub 2011 May 18.
2
[Age-related Macular Degeneration in the Japanese].[日本的年龄相关性黄斑变性]
Nippon Ganka Gakkai Zasshi. 2016 Mar;120(3):163-88; discussion 189.
3
Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.玻璃体内曲安奈德治疗年龄相关性黄斑变性的临床证据。
Curr Drug Targets. 2011 Feb;12(2):149-72. doi: 10.2174/138945011794182746.
4
Evolution of oxidative stress, inflammation and neovascularization in the choroid and retina in a subretinal lipid induced age-related macular degeneration model.在亚视网膜脂质诱导的年龄相关性黄斑变性模型中，脉络膜和视网膜中的氧化应激、炎症和新生血管的演变。
Exp Eye Res. 2021 Feb;203:108391. doi: 10.1016/j.exer.2020.108391. Epub 2020 Dec 8.
5
PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.接受抗血管内皮生长因子治疗的新生血管性年龄相关性黄斑变性患者黄斑萎缩的进展
Retina. 2016 Oct;36(10):1843-50. doi: 10.1097/IAE.0000000000001059.
6
[Morphology of outer retinal tubulations in the outcome of exudative age-related macular degeneration according to optical coherence tomography angiography].[基于光学相干断层扫描血管造影术的渗出性年龄相关性黄斑变性结局中外层视网膜管状结构的形态学]
Vestn Oftalmol. 2021;137(4):72-80. doi: 10.17116/oftalma202113704172.
7
Anti-Vascular Endothelial Growth Factor Resistance in Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy.渗出性黄斑变性和息肉状脉络膜血管病变中的抗血管内皮生长因子耐药性
Ophthalmol Retina. 2019 Sep;3(9):744-752. doi: 10.1016/j.oret.2019.04.018. Epub 2019 Apr 24.
8
Histopathology of Age-Related Macular Degeneration and Implications for Pathogenesis and Therapy.年龄相关性黄斑变性的组织病理学及其对发病机制和治疗的影响。
Adv Exp Med Biol. 2021;1256:67-88. doi: 10.1007/978-3-030-66014-7_3.
9
Inflammatory cytokines in aqueous humor of patients with choroidal neovascularization.脉络膜新生血管患者房水中的炎性细胞因子。
Mol Vis. 2012;18:574-80. Epub 2012 Mar 2.
10
Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.一种用于治疗渗出性年龄相关性黄斑变性的抗血管内皮生长因子聚乙二醇化适配体（EYE001）的临床前和1A期临床评估
Retina. 2002 Apr;22(2):143-52. doi: 10.1097/00006982-200204000-00002.

引用本文的文献

1
Measuring image distortions arising from age-related macular degeneration: An Iterative Amsler Grid (IAG).测量年龄相关性黄斑变性引起的图像畸变：迭代阿姆斯勒方格表（IAG）。
MedComm (2020). 2022 Mar 4;3(1):e107. doi: 10.1002/mco2.107. eCollection 2022 Mar.
2
Effects of major ozonated autohemotherapy in the treatment of dry age related macular degeneration: a randomized controlled clinical study.大剂量臭氧自血疗法治疗干性年龄相关性黄斑变性的疗效：一项随机对照临床研究。
Int J Ophthalmol. 2012;5(6):708-13. doi: 10.3980/j.issn.2222-3959.2012.06.11. Epub 2012 Dec 18.
3
Visual search with image modification in age-related macular degeneration.

本文引用的文献

1
Pathologic insights from integrated imaging of reticular pseudodrusen in age-related macular degeneration.年龄相关性黄斑变性中网状假性硬性渗出的综合影像学病理分析。
Retina. 2011 Mar;31(3):518-26. doi: 10.1097/IAE.0b013e3181f04974.
2
Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.每月与每季度雷珠单抗治疗新生血管性年龄相关性黄斑变性的疗效和安全性：EXCITE 研究。
Ophthalmology. 2011 May;118(5):831-9. doi: 10.1016/j.ophtha.2010.09.004. Epub 2010 Dec 13.
3
Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography.
与年龄相关性黄斑变性相关的图像修改的视觉搜索。
Invest Ophthalmol Vis Sci. 2012 Sep 25;53(10):6600-9. doi: 10.1167/iovs.12-10012.
利用频域光学相干断层扫描成像观察年龄相关性黄斑变性的地理萎缩进展。
Ophthalmology. 2011 Apr;118(4):679-86. doi: 10.1016/j.ophtha.2010.08.018. Epub 2010 Oct 29.
4
Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration.雷珠单抗联合维速达尔研究：确定维替泊芬光动力疗法联合玻璃体内注射雷珠单抗治疗渗出性黄斑变性的阈剂量能量密度
Clin Ophthalmol. 2010 Oct 5;4:1073-9. doi: 10.2147/OPTH.S13969.
5
Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration.与年龄相关性黄斑变性治疗相关的死亡、心肌梗死、出血和中风风险。
Arch Ophthalmol. 2010 Oct;128(10):1273-9. doi: 10.1001/archophthalmol.2010.223.
6
Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial.OT-551 局部给药治疗地图状萎缩的 II 期临床试验结果。
Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6131-9. doi: 10.1167/iovs.10-5637. Epub 2010 Jun 23.
7
Protection of retinal pigment epithelium by OT-551 and its metabolite TEMPOL-H against light-induced damage in rats.OT-551 及其代谢产物 TEMPOL-H 对大鼠光诱导损伤的视网膜色素上皮细胞的保护作用。
Exp Eye Res. 2010 Jul;91(1):111-4. doi: 10.1016/j.exer.2010.04.012. Epub 2010 Apr 29.
8
The multifunctional choroid.多功能脉络膜。
Prog Retin Eye Res. 2010 Mar;29(2):144-68. doi: 10.1016/j.preteyeres.2009.12.002. Epub 2009 Dec 29.
9
Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting.雷珠单抗治疗渗出性年龄相关性黄斑变性：单中心机构设置的 24 个月结果。
Br J Ophthalmol. 2010 Mar;94(3):292-6. doi: 10.1136/bjo.2009.170670. Epub 2009 Dec 1.
10
Deal watch: Alcon licenses complement pathway inhibitor for macular degeneration.交易观察：爱尔康获得黄斑变性补体通路抑制剂许可。
Nat Rev Drug Discov. 2009 Dec;8(12):922. doi: 10.1038/nrd3063.